Dyne Therapeutics, Inc.

NasdaqGS DYN

Dyne Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 402.98

Dyne Therapeutics, Inc. Price to Sales Ratio (P/S) is 402.98 on January 14, 2025, a 11.61% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Dyne Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 1,158.84 on August 21, 2024, which is 187.57% above the current Price to Sales Ratio (P/S).
Dyne Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 337.12 on January 19, 2024, which is -16.34% below the current Price to Sales Ratio (P/S).
Dyne Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 747.07.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: DYN

Dyne Therapeutics, Inc.

CEO	Mr. John G. Cox M.B.A.
IPO Date	Sept. 17, 2020
Location	United States
Headquarters	1560 Trapelo Road
Employees	173
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Key trends

Past 5 years